Skip to main content

Advertisement

Advertisement

Asia

COVAX expects full vaccine supplies from India's Serum in May, says UNICEF

COVAX expects full vaccine supplies from India's Serum in May, says UNICEF

FILE PHOTO: A vial with AstraZeneca's COVID-19 vaccine is prepared during a vaccination of teachers and nursery teachers, amid the spread of the coronavirus disease (COVID-19), in Grevesmuehlen, Germany, March 5, 2021. REUTERS/Fabian Bimmer/File Photo

NEW DELHI: A World Health Organization (WHO)-backed programme to supply coronavirus vaccines to poorer countries expects that the Serum Institute of India (SII) will resume full deliveries of the AstraZeneca shot to it in May, UNICEF said on Saturday (Mar 27).

"Deliveries of SII/AZ vaccine are expected to begin fully again by May, with catch-up deliveries to reach every participant’s full allocation up to May, accelerating thereafter," a UNICEF spokeswoman told Reuters in an email.

The spokeswoman added that the programme, known as COVAX, was in talks with New Delhi to secure "some supply" in April too. COVAX was expecting a total of 90 million doses from SII in March and April, of which it has received about 28 million.

UNICEF is the distributing partner of the programme, run with the GAVI vaccine alliance.

India, the world's biggest vaccine maker, said on Friday it would make domestic COVID-19 inoculations a priority as infections surge, and had told international buyers of its decision.

WHO Director-General Tedros Adhanom Ghebreyesus said on Friday that India's decision was "understandable" but that the WHO was in talks so it continues providing doses to other countries.

So far COVAX has delivered 32 million vaccine doses to 61 countries, but 36 countries still await vaccines to start inoculations, Tedros said.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters

Advertisement

Also worth reading

Advertisement